Development of the Rat Model of Lapatinib-Induced Diarrhoea

Abstract EN

Targeted therapy of cancer is often associated with clinically significant diarrhoea; however, the mechanisms underpinning this adverse effect are currently unknown.

Diarrhoea following treatment with tyrosine kinase inhibitors (TKIs) of EGFR is particularly troublesome.

Until recently, understanding of EGFR TKI-induced diarrhoea has been limited to clinical observation.

However, our group has recently developed the first rat model of EGFR TKI-induced diarrhoea.

This paper reviews the published and unpublished findings.